Compounds > imatinib mesylate
Page last updated: 2024-09-03

imatinib mesylate and Multiple Myeloma

imatinib mesylate has been researched along with Multiple Myeloma in 31 studies

Research

Studies (31)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's17 (54.84)29.6817
2010's11 (35.48)24.3611
2020's3 (9.68)2.80

Authors

AuthorsStudies
Allahyari, A; Jafari-Nozad, AM; Maharati, A; Zangooie, A1
Suzuki, K1
Dourado, C; Gupta, S; Swaminathan, N1
Abdulkadyrov, KM; Bessmel'tsev, SS; Martynkevich, IS; Romanenko, NA; Rugal', VI; Udal'eva, VIu; Zenina, MN1
Borchmann, P; Engert, A; Monsef, I; Rancea, M; Skoetz, N; Will, A1
Augustyniak, D; Bartkowiak, A; Goffeau, A; Gonchar, M; Ko, YH; Lis, P; Majkowska-Skrobek, G; Pedersen, PL; Ułaszewski, S1
Ohashi, K1
Ahn, S; Cho, SR; Han, JH; Park, JS1
Asara, JM; Breitkopf, SB; Helenius, KP; Lyssiotis, CA; Yuan, M1
Cheng, T; Gao, J; Gao, YD; Gao, YN; Li, MH; Li, Y; Li, YX; Wang, XM; Xu, QZ; Yuan, WP1
Heidel, FH; Wolleschak, D1
Birgens, H; Brown, Pde N; Dalseg, AM; Dufva, IH; Hasselbalch, HC; Jensen, MK; Vangsted, A1
Anagnostopoulos, NI; Galanopoulos, A; Georgiakaki, M; Kritikou-Griva, E; Papadhimitriou, SI1
Huang, BH; Li, J; Luo, SK; Zhao, Y1
Antoniades, M; Lemesiou, E; Melanthiou, F; Michael, M; Papaminas, N1
Bai, LY; Chiu, CF; Lin, CW; Sargeant, A; Tsai, CH; Weng, JR1
Ruiz-Argüelles, GJ1
Gondo, H; Ide, M; Kimura, S; Kuwahara, N; Matsuishi, E1
Cohen, MH; Dagher, R; Griebel, DJ; Ibrahim, A; Martin, A; Pazdur, R; Scher, NS; Sokol, GH; Williams, GA1
Carvajal-Vergara, X; Gutiérrez, N; Mateo, G; Pandiella, A; San Miguel, JF; Tabera, S1
Dirnhofer, S; Khanlari, B; Lugli, A; Nikolova, Z; Went, P1
Kees, UR1
Wiernik, PH1
Bakhanashvili, M; Beery, E; Birenbaum, M; Fenig, E; Lahav, M; Luria, D; Nordenberg, J; Reshef, H; Sandbank, J; Uziel, O; Yerushalmi, R1
Allred, J; Dispenzieri, A; Fonseca, R; Gertz, MA; Geyer, SM; Greipp, PR; Kimlinger, T; Lacy, MQ; Lust, JA; Rajkumar, SV; Witzig, TE1
Bai, QX; Chen, XQ; Dong, BX; Gao, GX; Gu, HT; Pan, YZ; Zhang, YQ; Zhu, HF1
Anderson, KC; Barilà, D; Chauhan, D; DePinho, RA; Hideshima, T; Podar, K; Raab, MS; Raje, N; Sattler, M; Tai, YT; Tonon, G; Yasui, H; Zhang, J1
Apperley, JF; Chaidos, A; Kanfer, E1
Gatopoulou, A; Katodritou, E; Katsos, I; Patakiouta, F; Tarpagos, A; Tzilves, D; Zervas, K1
Gupta, S; Janz, S; Lee, JS; Mushinski, JF; Owens, JD; Park, ES; Potter, M; Shaughnessy, JD; Wang, H; Woo, HG; Zhan, F1
Brazier, M; Dib, IE; El Hajj Dib, I; Gressier, M; Kamel, S; Mélanie, G; Mentaverri, R; Michel, B; Romuald, M; Salle, V; Valery, S1

Reviews

6 review(s) available for imatinib mesylate and Multiple Myeloma

ArticleYear
Prostate cancer, chronic myelogenous leukemia and multiple myeloma in a single patient: a case report and review of the literature.
    Journal of medical case reports, 2023, Feb-05, Volume: 17, Issue:1

    Topics: Aged, 80 and over; Humans; Imatinib Mesylate; Iran; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Multiple Myeloma; Prostatic Neoplasms; Protein Kinase Inhibitors

2023
[Novel medical treatment modalities in hematology].
    Ugeskrift for laeger, 2008, Jun-09, Volume: 170, Issue:24

    Topics: Aminoglycosides; Anemia, Hemolytic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Benzoates; Boronic Acids; Bortezomib; Carbazoles; Carrier Proteins; Cyclophosphamide; Dasatinib; Furans; Gemtuzumab; Hematologic Diseases; Humans; Hydrazines; Imatinib Mesylate; Immunologic Factors; Indoles; Lenalidomide; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Piperazines; Purpura, Thrombocytopenic; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Thalidomide; Thiazoles; Thrombopoietin; Vidarabine

2008
Uncommon case of chronic myeloid leukemia with multiple myeloma.
    International journal of hematology, 2010, Volume: 91, Issue:4

    Topics: Aged; Antineoplastic Agents; Benzamides; Bone Marrow; Female; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Multiple Myeloma; Piperazines; Pyrimidines

2010
Plasma cell myeloma and leukemia.
    Cancer chemotherapy and biological response modifiers, 2003, Volume: 21

    Topics: Adult; Antineoplastic Agents; Benzamides; Child; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia; Multiple Myeloma; Piperazines; Pyrimidines

2003
Risk assessment in haemotopoietic stem cell transplantation: disease and disease stage.
    Best practice & research. Clinical haematology, 2007, Volume: 20, Issue:2

    Topics: Acute Disease; Adult; Benzamides; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasm Staging; Neoplasms; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Pyrimidines; Recurrence; Risk Assessment; Survival Analysis; Transplantation, Homologous

2007
Gene expression profiling reveals different pathways related to Abl and other genes that cooperate with c-Myc in a model of plasma cell neoplasia.
    BMC genomics, 2007, Aug-31, Volume: 8

    Topics: Animals; Benzamides; Cell Line, Tumor; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, abl; Genes, myc; Humans; Imatinib Mesylate; Lymphoma, B-Cell; Mice; Mice, Inbred BALB C; Models, Biological; Multiple Myeloma; Neoplasms, Plasma Cell; Piperazines; Pyrimidines; Signal Transduction; STAT Transcription Factors

2007

Trials

1 trial(s) available for imatinib mesylate and Multiple Myeloma

ArticleYear
A phase II trial of imatinib in patients with refractory/relapsed myeloma.
    Leukemia & lymphoma, 2006, Volume: 47, Issue:1

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cell Proliferation; Disease Progression; Disease-Free Survival; Female; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Male; Middle Aged; Multiple Myeloma; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Recurrence; Retrospective Studies; Survival Rate; Time Factors; Treatment Failure

2006

Other Studies

24 other study(ies) available for imatinib mesylate and Multiple Myeloma

ArticleYear
[Progress of MM/CML treatment and medical economics].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2020, Volume: 61, Issue:6

    Topics: Antineoplastic Agents; Economics, Medical; Humans; Imatinib Mesylate; Japan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Multiple Myeloma; Protein Kinase Inhibitors

2020
Case Report: IgG multiple myeloma and chronic myeloid leukemia in a single patient.
    F1000Research, 2020, Volume: 9

    Topics: Bortezomib; Dexamethasone; Humans; Imatinib Mesylate; Immunoglobulin G; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Thalidomide

2020
[The combination of chronic myeloid leukemia and multiple myeloma in one patient].
    Voprosy onkologii, 2013, Volume: 59, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Imatinib Mesylate; Induction Chemotherapy; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Molecular Targeted Therapy; Multiple Myeloma; Piperazines; Polyneuropathies; Pyrazines; Pyrimidines; Recurrence; Watchful Waiting

2013
Fifteenth biannual report of the Cochrane Haematological Malignancies Group--focus on non-Hodgkin's lymphoma.
    Journal of the National Cancer Institute, 2013, Aug-07, Volume: 105, Issue:15

    Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bleomycin; Cyclophosphamide; Dasatinib; Doxorubicin; Etoposide; Hodgkin Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma, Non-Hodgkin; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Neoplasm Staging; Piperazines; Platelet Transfusion; Prednisone; Primary Prevention; Procarbazine; Pyrimidines; Randomized Controlled Trials as Topic; Rituximab; Stem Cell Transplantation; Survival Analysis; Thiazoles; Thrombocytopenia; Transplantation, Autologous; Treatment Outcome; Vincristine; Vindesine

2013
Killing multiple myeloma cells with the small molecule 3-bromopyruvate: implications for therapy.
    Anti-cancer drugs, 2014, Volume: 25, Issue:6

    Topics: Adenosine Triphosphate; Antineoplastic Agents; Benzamides; Buthionine Sulfoximine; Cell Survival; Glutathione; Humans; Imatinib Mesylate; Inhibitory Concentration 50; Lactic Acid; Monocarboxylic Acid Transporters; Multiple Myeloma; Piperazines; Pyrimidines; Pyruvates; Symporters; Tumor Cells, Cultured

2014
[Overview].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2015, Volume: 56, Issue:3

    Topics: Animals; Benzamides; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Multiple Myeloma; Piperazines; Prognosis; Pyrimidines; Thalidomide

2015
A rare case of chronic myelogenous leukemia and plasma cell myeloma in the same patient.
    Annals of laboratory medicine, 2015, Volume: 35, Issue:3

    Topics: Aged; Antineoplastic Agents; Bone Marrow; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Male; Multiple Myeloma; Platelet Count; Polymerase Chain Reaction; Thrombocytosis

2015
Triomics Analysis of Imatinib-Treated Myeloma Cells Connects Kinase Inhibition to RNA Processing and Decreased Lipid Biosynthesis.
    Analytical chemistry, 2015, Nov-03, Volume: 87, Issue:21

    Topics: Antineoplastic Agents; Cell Line, Tumor; Humans; Imatinib Mesylate; Lipids; Multiple Myeloma; RNA Processing, Post-Transcriptional

2015
[Effect of TEB-415, a Derivative of Imatinib, on Multiple Myeloma].
    Zhongguo shi yan xue ye xue za zhi, 2016, Volume: 24, Issue:3

    Topics: Apoptosis; Bortezomib; Cell Line, Tumor; Humans; Imatinib Mesylate; Multiple Myeloma

2016
Chronic myelogenous leukemia evolving after treatment of multiple myeloma.
    Blood, 2016, 07-07, Volume: 128, Issue:1

    Topics: Antineoplastic Agents; Bone Marrow; Bortezomib; Dexamethasone; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Multiple Myeloma

2016
Multiple myeloma developing after imatinib mesylate therapy for chronic myeloid leukemia.
    Annals of hematology, 2009, Volume: 88, Issue:3

    Topics: Aged; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Multiple Myeloma; Piperazines; Pyrimidines

2009
[Imatinib induces c-kit positive myeloma cells apoptosis].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2008, Volume: 29, Issue:4

    Topics: Apoptosis; Benzamides; Cell Cycle; Cell Differentiation; Cell Line, Tumor; Humans; Imatinib Mesylate; Multiple Myeloma; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines

2008
Development of multiple myeloma in a patient with chronic myeloid leukemia while on treatment with imatinib mesylate for 65 months.
    The oncologist, 2009, Volume: 14, Issue:12

    Topics: Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Multiple Myeloma; Piperazines; Protein Kinase Inhibitors; Pyrimidines

2009
OSU-03012 sensitizes TIB-196 myeloma cells to imatinib mesylate via AMP-activated protein kinase and STAT3 pathways.
    Leukemia research, 2010, Volume: 34, Issue:6

    Topics: AMP-Activated Protein Kinases; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Synergism; HL-60 Cells; Humans; Imatinib Mesylate; Multiple Myeloma; Piperazines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Signal Transduction; STAT3 Transcription Factor; Sulfonamides; Time Factors

2010
Whither the bone marrow transplant?
    Hematology (Amsterdam, Netherlands), 2010, Volume: 15, Issue:1

    Topics: Antineoplastic Agents; Benzamides; Bone Marrow Transplantation; Developed Countries; Developing Countries; Drug Costs; Drug Utilization; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Melphalan; Mexico; Multiple Myeloma; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Spain; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; United States

2010
U.S. Food and Drug Administration drug approval summaries: imatinib mesylate, mesna tablets, and zoledronic acid.
    The oncologist, 2002, Volume: 7, Issue:5

    Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Bone Neoplasms; Cystitis; Diphosphonates; Drug Approval; Gastrointestinal Neoplasms; Hematuria; Hemorrhage; Humans; Ifosfamide; Imatinib Mesylate; Imidazoles; Mesna; Multiple Myeloma; Orphan Drug Production; Piperazines; Protective Agents; Pyrimidines; Randomized Controlled Trials as Topic; United States; United States Food and Drug Administration; Zoledronic Acid

2002
Imatinib mesylate (STI571) inhibits multiple myeloma cell proliferation and potentiates the effect of common antimyeloma agents.
    British journal of haematology, 2003, Volume: 123, Issue:5

    Topics: Antineoplastic Agents; Benzamides; Cell Cycle; Cell Division; Cell Line, Tumor; Dexamethasone; Drug Synergism; Enzyme Activation; Flow Cytometry; Humans; Imatinib Mesylate; Mitogen-Activated Protein Kinases; Multiple Myeloma; Piperazines; Protein-Tyrosine Kinases; Pyrimidines

2003
Rare KIT (CD117) expression in multiple myeloma abrogates the usefulness of imatinib mesylate treatment.
    Virchows Archiv : an international journal of pathology, 2004, Volume: 444, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Benzamides; Enzyme Inhibitors; Female; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Middle Aged; Multiple Myeloma; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines

2004
Gene expression signatures in lymphoid tumours.
    Immunology and cell biology, 2004, Volume: 82, Issue:2

    Topics: Antineoplastic Agents; Benzamides; Gene Expression; Gene Expression Profiling; Humans; Imatinib Mesylate; Leukemia; Lymphoma; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; Piperazines; Pyrimidines; RNA, Messenger

2004
Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines.
    British journal of cancer, 2005, May-23, Volume: 92, Issue:10

    Topics: Animals; Antineoplastic Agents; Benzamides; Breast Neoplasms; Cell Proliferation; Dose-Response Relationship, Drug; Down-Regulation; Fanconi Anemia; Humans; Imatinib Mesylate; Melanoma; Mice; Multiple Myeloma; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Sarcoma, Ewing; Skin Neoplasms; Telomerase; Tumor Cells, Cultured

2005
[Tyrosine kinase inhibitor reverses adriamycin resistance mediated by cell adhesion in RPMI8226 cells].
    Zhongguo shi yan xue ye xue za zhi, 2006, Volume: 14, Issue:2

    Topics: Benzamides; Cell Adhesion; Doxorubicin; Drug Resistance, Neoplasm; Fibronectins; Humans; Imatinib Mesylate; Multiple Myeloma; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; rac1 GTP-Binding Protein; RNA, Messenger; Tumor Cells, Cultured

2006
Up-regulation of c-Jun inhibits proliferation and induces apoptosis via caspase-triggered c-Abl cleavage in human multiple myeloma.
    Cancer research, 2007, Feb-15, Volume: 67, Issue:4

    Topics: Adamantane; Apoptosis; Benzamides; Boronic Acids; Bortezomib; Caspase Inhibitors; Caspases; Cell Growth Processes; Dexamethasone; Humans; Hydroquinones; Imatinib Mesylate; Leukemia, Erythroblastic, Acute; Melphalan; Multiple Myeloma; Piperazines; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-jun; Pyrazines; Pyrimidines; Transfection; Up-Regulation

2007
Development of multiple myeloma in a patient with gastrointestinal stromal tumor treated with imatinib mesylate: a case report.
    World journal of gastroenterology, 2007, Apr-07, Volume: 13, Issue:13

    Topics: Aged; Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Multiple Myeloma; Neoplasms, Multiple Primary; Piperazines; Pyrimidines

2007
Multiple myeloma cells directly stimulate bone resorption in vitro by down-regulating mature osteoclast apoptosis.
    Leukemia research, 2008, Volume: 32, Issue:8

    Topics: Apoptosis; Benzamides; Bone Resorption; Cell Line, Tumor; Cell Survival; Culture Media, Conditioned; Down-Regulation; Humans; Imatinib Mesylate; Macrophage Colony-Stimulating Factor; Multiple Myeloma; Osteoclasts; Piperazines; Pyrimidines; Signal Transduction

2008